Effectiveness of Anti-osteoporotic Drugs to Prevent Secondary Fragility Fractures: Systematic Review and Meta-analysis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2017 Aug 4

PMID 28770272

Citations 48

Authors

T Saito

J M Sterbenz

S Malay

L Zhong

M P MacEachern

K C Chung

Affiliations

Soon will be listed here.

Abstract

Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com , and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38-0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

Citing Articles

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis.

Yang J, Guo X, Cui Z, Guo H, Dong J Front Endocrinol (Lausanne). 2024; 15:1431676.

PMID: 39286276 PMC: 11402677. DOI: 10.3389/fendo.2024.1431676.

The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials.

Zeng Y, Yang Y, Wang J, Meng G Osteoporos Int. 2024; 35(11):1897-1907.

PMID: 39115687 PMC: 11499321. DOI: 10.1007/s00198-024-07191-5.

Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.

Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T Health Technol Assess. 2024; 28(21):1-169.

PMID: 38634483 PMC: 11056815. DOI: 10.3310/WYPF0472.

The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.

Agarwal A, Kinnard M, Murdock C, Zhao A, Ahiarakwe U, Cohen J Osteoporos Int. 2024; 35(7):1223-1229.

PMID: 38619605 DOI: 10.1007/s00198-024-07085-6.

Return on investment of fracture liaison services: a systematic review and analysis.

Xu L, Zhao T, Perry L, Frost S, Di Tanna G, Wang S Osteoporos Int. 2024; 35(6):951-969.

PMID: 38300316 DOI: 10.1007/s00198-024-07027-2.

References

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Peichl P, Holzer L, Maier R, Holzer G . Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011; 93(17):1583-7. DOI: 10.2106/JBJS.J.01379. View

Inderjeeth C, Chan K, Kwan K, Lai M . Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab. 2012; 30(5):493-503. DOI: 10.1007/s00774-012-0349-1. View

Chesnut 3rd C, Silverman S, Andriano K, Genant H, Gimona A, Harris S . A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4):267-76. DOI: 10.1016/s0002-9343(00)00490-3. View

Marsh D, Akesson K, Beaton D, Bogoch E, Boonen S, Brandi M . Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22(7):2051-65. DOI: 10.1007/s00198-011-1642-x. View

Delmas P, Genant H, Crans G, Stock J, Wong M, Siris E . Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003; 33(4):522-32. DOI: 10.1016/s8756-3282(03)00241-2. View

Brumsen C, Papapoulos S, Lips P, Geelhoed-Duijvestijn P, Hamdy N, Landman J . Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res. 2002; 17(6):1057-64. DOI: 10.1359/jbmr.2002.17.6.1057. View

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD003376. PMC: 6999803. DOI: 10.1002/14651858.CD003376.pub3. View

10.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

11.

Nakayama A, Major G, Holliday E, Attia J, Bogduk N . Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2015; 27(3):873-879. PMC: 4767862. DOI: 10.1007/s00198-015-3443-0. View

12.

Maclean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2007; 148(3):197-213. DOI: 10.7326/0003-4819-148-3-200802050-00198. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

14.

Clemmesen B, Ravn P, Zegels B, Taquet A, Christiansen C, Reginster J . A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int. 1997; 7(5):488-95. DOI: 10.1007/pl00004152. View

15.

Harris S, Watts N, Jackson R, Genant H, Wasnich R, Ross P . Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993; 95(6):557-67. DOI: 10.1016/0002-9343(93)90350-x. View

16.

Wimalawansa S . A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998; 104(3):219-26. DOI: 10.1016/s0002-9343(98)00029-1. View

17.

Akesson K, Marsh D, Mitchell P, McLellan A, Stenmark J, Pierroz D . Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013; 24(8):2135-52. PMC: 3706734. DOI: 10.1007/s00198-013-2348-z. View

18.

Hodsman A, Hanley D, Josse R . Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002; 166(11):1426-30. PMC: 111217. View

19.

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

20.

Lindsay R, Nieves J, Formica C, HENNEMAN E, Woelfert L, Shen V . Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350(9077):550-5. DOI: 10.1016/S0140-6736(97)02342-8. View